OTCMKTS:CHGCY Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis $23.80 +0.66 (+2.85%) As of 11:23 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock About Chugai Pharmaceutical Stock (OTCMKTS:CHGCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Chugai Pharmaceutical alerts:Sign Up Key Stats Today's Range$23.59▼$24.0550-Day Range$23.14▼$29.2752-Week Range$19.50▼$34.84Volume80,915 shsAverage Volume228,367 shsMarket Capitalization$78.34 billionP/E Ratio26.44Dividend Yield2.61%Price TargetN/AConsensus RatingBuy Company Overview Chugai Pharmaceutical Co., Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support. Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics. One of its best-known products is tocilizumab (marketed in many territories through collaborative arrangements), reflecting the company’s capabilities in immunology and antibody engineering. Chugai’s product portfolio and pipeline include both in-house assets and programs developed in collaboration with external partners, demonstrating a mix of internal R&D and strategic alliances to advance new medicines. Chugai maintains a long-standing strategic partnership with the Roche Group and operates primarily in the Japanese market while leveraging global commercialization channels through alliances. The company supports clinical development and manufacturing activities in Japan and engages with international partners to expand the reach of its therapies. Chugai is managed by a professional leadership and scientific team with experience in pharmaceutical R&D and commercial operations, and it positions itself as a research-oriented company within the global biopharmaceutical landscape.AI Generated. May Contain Errors. Read More Chugai Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreCHGCY MarketRank™: Chugai Pharmaceutical scored higher than 68% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingBuy Consensus RatingChugai Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageChugai Pharmaceutical has only been the subject of 1 research reports in the past 90 days.Read more about Chugai Pharmaceutical's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth30.61% Earnings GrowthEarnings for Chugai Pharmaceutical are expected to grow by 30.61% in the coming year, from $0.98 to $1.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chugai Pharmaceutical is 25.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Chugai Pharmaceutical is 25.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.12.Price to Book Value per Share RatioChugai Pharmaceutical has a P/B Ratio of 5.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Chugai Pharmaceutical's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Chugai Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverChugai Pharmaceutical has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chugai Pharmaceutical has recently decreased by 97.22%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldChugai Pharmaceutical pays a meaningful dividend of 2.61%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthChugai Pharmaceutical does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Chugai Pharmaceutical is 68.89%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Chugai Pharmaceutical will have a dividend payout ratio of 48.44% next year. This indicates that Chugai Pharmaceutical will be able to sustain or increase its dividend.Read more about Chugai Pharmaceutical's dividend. News and Social Media2.5 / 5News SentimentN/A News SentimentChugai Pharmaceutical has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Chugai Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Institutions0.01% of the stock of Chugai Pharmaceutical is held by institutions.Read more about Chugai Pharmaceutical's insider trading history. Receive CHGCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chugai Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CHGCY Stock News HeadlinesChugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call TranscriptJanuary 29, 2026 | seekingalpha.comChugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DMENovember 25, 2025 | finanznachrichten.deNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Central banks bought a record 863 tonnes in 2025 alone - and one small-cap explorer in Nevada's Walker Lane Belt may be positioned to benefit. Sitting 18 miles north of Tonopah in the same district that produced over 15 million ounces at Kinross Gold's Round Mountain Mine, this explorer carries historic drill intercepts of 30 meters at 2.5 g/t gold and surface samples exceeding 100 g/t. With a market cap under $15 million and drills ready to turn in H2 2026, the window may be narrow.June 4 at 1:00 AM | Wall Street Logic (Ad)Chugai Pharmaceutical to Merge with Renalys Pharma to Boost Kidney Disease Drug DevelopmentNovember 18, 2025 | msn.comRani Therapeutics Shares Double After Deal With Chugai PharmaOctober 17, 2025 | marketwatch.comRani Therapeutics surges on Chugai licensing deal, private placementOctober 17, 2025 | msn.comRani Therapeutics Holdings Inc. inks $1.085 billion collaboration with Chugai Pharmaceutical Co. Ltd.October 17, 2025 | msn.comChugai Announces Positive Phase 3 Results for Eli Lilly’s OrforglipronAugust 28, 2025 | msn.comSee More Headlines CHGCY Stock Analysis - Frequently Asked Questions How have CHGCY shares performed this year? Chugai Pharmaceutical's stock was trading at $26.27 at the start of the year. Since then, CHGCY shares have decreased by 11.9% and is now trading at $23.14. How were Chugai Pharmaceutical's earnings last quarter? Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) posted its quarterly earnings results on Friday, April, 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The company earned $2.05 billion during the quarter. Chugai Pharmaceutical had a trailing twelve-month return on equity of 22.90% and a net margin of 34.98%. How do I buy shares of Chugai Pharmaceutical? Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings4/24/2026Today6/04/2026Next Earnings (Estimated)7/23/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:CHGCY CIK1453934 Webwww.chugai-pharm.co.jp Phone(133) 281-6611FaxN/AEmployees7,778Year Founded1925Profitability EPS (Trailing Twelve Months)$0.90 Trailing P/E Ratio26.44 Forward P/E Ratio24.29 P/E GrowthN/ANet Income$2.91 billion Net Margins34.98% Pretax Margin47.52% Return on Equity22.90% Return on Assets19.45% Debt Debt-to-Equity RatioN/A Current Ratio4.70 Quick Ratio3.82 Sales & Book Value Annual Sales$8.41 billion Price / Sales9.31 Cash Flow$0.95 per share Price / Cash Flow25.10 Book Value$4.12 per share Price / Book5.78Miscellaneous Outstanding Shares3,291,430,000Free FloatN/AMarket Cap$78.34 billion OptionableNot Optionable Beta0.58 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:CHGCY) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredTrump’s New Dollar revealedThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredThe SpaceX S-1 changes everythingSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chugai Pharmaceutical Co., Ltd. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chugai Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
